REPORTS AND PUBLICATIONS
The International Journal of Tuberculosis and Lung Disease has released its May publication featuring RESIST-TB Steering Committee members Dr. C. Robert Horsburgh and Dr. Carole Mitnick as guest editors. The issue also features articles written by a number of RESIST-TB members and partners. Please see a full list of articles below:
Our Annual Report details the progress that each working group made in 2021, as well as sets goals for 2022.
Our Annual Report details the progress that each working group made in 2020, as well as sets goals for 2021.
Our Annual Report details the progress that each working group made in 2019, as well as sets goals for 2020.
K. Held, S. McAnaw, C-Y. Chiang, A. Trebucq, C. R. Horsburgh, Jr.
K. Mezwa, S. McAnaw, C-Y. Chiang, A. Trébucq, C. R. Horsburgh
A State of the Art Article Krakauer, E. L.; Dheda, K.; Kalsdorf, B.; Kuksa, L.; Nadkarni, A.; Nhung, N. V.; Selwyn, P.; Shin, S.; Skrahina, A.; Jaramillo, E.
A State of the Art Article, E. A. Talbot, M. Pai
A State of the Art Article, C. Lange, R. E. Aarnoutse, J. W. C. Alffenaar, G. Bothamley, F. Brinkmann, J. Costa, D. Chesov, R. van Crevel, M. Dedicoat, J. Dominguez, R. Duarte, H. P. Grobbel, G. Gunther, L. Guglielmetti, J. Heyckendorf, A. W. Kay, O. Kirakosyan, O. Kirk, R. A. Koczulla, G. G. Kudriashov, L. Kuksa, F. van Leth, C. Magis-Escurra, A. M. Mandalakas, B. Molina-Moya, C. A. Peloquin, M. Reimann, R. Rumetshofer, H. S. Schaaf, T. Sch ¨on, S. Tiberi, J. Valda, P. K. Yablonskii, K. Dheda
Series editors: Horsburgh, C. R; Lange, C.; Mitnick, C
A State of the Art Article, Cox V.; Cox, H.; Pai, M.; Stillo, J.; Citro, B.; Brigden, G.
Horsburgh C. R.; Mitnick, C. D.; Lange, C.
A State of the Art Article, Kendall E. A.; Sahu, S.; Pai, M.; Fox, G. J.; Varaine, F.; Cox, H.; Cegielski, J. P.; Mabote, L.; Vassall, A.; Dowdy, D. W.
State of the Art Article, Nathavitharana R. R.; Lederer, P.; Tierney, D. B.; Nardell, E.
Our Annual Report details the progress that each working group made in 2018, as well as sets goals for 2019.
Horsburgh C.R., Chiang C-Y, Trébucq A, Mezwa K, Held K
Mcanaw S, Muller A, Mitnick C, Horsburgh C.R.
Hoddinott G, Staples S, Brown R, Simwinga M, Mubekapi-Musadaidzwa C, Hesseling AC, Hendricks G, De Koker P, McKenna L
Seddon JA, Weld ED, Schaaf HS, Garcia-Prats AJ, Kim S, Hesseling AC
Kim S, Seddon JA, Garcia-Prats AJ, Montepiedra G
Garcia-Prats AJ, Svensson EM, Weld ED, Schaaf HS, Hesseling AC
Tucker EW, Dooley KE
Jenkins HE, Yuen CM
Horsburgh C.R, Gupta A
Our Annual Report details the progress that each working group made in 2017, as well as sets goals for 2018.
Mezwa K, McAnaw S, Chiang C-Y, Trébucq A, Horsburgh C.R
RESIST-TB Site Development Report and Site Development Tool (2017)
The Site Development Report outlines efforts to expand the number of possible MDR-TB clinical trial sites in areas with access to patients and interest in becoming trial sites. RESIST-TB developed a Site Development Tool to determine whether those sites either had adequate capacity or needed site development activity.
Our Annual Report details the progress that each working group made in 2016, as well as sets goals for 2017.
There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains limited. This piece presents the third updated Research Agenda for the programmatic management of drug-resistant TB (PMDT), assembled through a literature review and survey.
(2016) Based on the results of the first global MDR-TB Clinical Trials Landscape meeting held in 2014, this supplement includes a collection of manuscripts that address key topics including both methodological issues and agent-specific reports. These articles provide an in-depth discussion of the rationale behind current MDR-TB clinical trials as well as important insights to drive future research.
With support from the Firland Foundation, RESIST-TB investigated mechanisms for accessing drugs prior to regulatory approval and surveyed key providers and advocates on their experience attempting to gain access to new TB drugs through compassionate use or similar pre-approval mechanisms. The findings from this project are detailed in this report, “Monitoring Compassionate Use of New Drugs for Tuberculosis.
Presents a core set of efficacy and safety definitions as well as other important considerations in DR-TB clinical trials work.
Proposes that reports of molecular DST results should include information on specific mutations that affect resistance to chose an appropriate treatment regimen.
Identifies priorities for coordinated research in PMDT that could fill longstanding gaps barring expanded treatment access, including: shorter treatment regimens, knowledge of disease burden without representative data, and treatment for latent TB infection in household contacts of known DR-TB patients.